Published online before print May 12, 2003, doi: 10.1161/01.CIR.0000070421.38604.2B
(Circulation. 2003;108:48.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy
From Columbia University, New York, NY.
Correspondence to Donna M. Mancini, MD, 622 West 168th St, New York, NY 10032. E-mail dmm31{at}columbia.edu
Received December 16, 2002; revision received March 4, 2003; accepted March 5, 2003.
Background— Cardiac transplantation vasculopathy is the leading cause of late death in heart transplantation recipients. Rapamycin is an immunosuppressant drug with potent antiproliferative and antimigratory effects. We investigated whether rapamycin could prevent progression of graft vasculopathy in 46 patients (age, 54±10 years; 4.3±2.3 years after transplantation) with severe disease.
Methods and Results— At annual cardiac catheterization, patients were randomly assigned to treatment with rapamycin (n=22) versus continued current immunosuppression (n=24). Clinical characteristics including recipient age and sex, underlying cause of congestive heart failure, donor age and sex, and ischemic time were recorded. Cardiac catheterization was graded with the use of a semiquantitative scale and repeated annually. Clinically significant adverse events were defined as death, need for angioplasty or bypass surgery, myocardial infarction, and a >25% worsening of the catheterization score. These events were monitored as primary study end points. Anti-HLA class I and II antibody production and lymphocyte growth assays were measured with each biopsy. Patients selected for rapamycin had azathioprine or mycophenolate mofetil discontinued and were given rapamycin. Outcomes were compared by means of log-rank analysis. There were no significant differences in baseline characteristics. Duration of follow-up was comparable (rapamycin, 689±261; control, 630±207 days; NS). In the rapamycin group, 3 patients reached primary end points versus 14 patients in the control group (P<0.001). There was no difference in baseline or subsequent anti-HLA class I or II antibody production.
Conclusions— In this patient cohort with cardiac vasculopathy, treatment with rapamycin slowed disease progression probably by its antiproliferative and antimigratory effects.
Key Words: transplantation • vasculature • atherosclerosis • drugs
Related Article:
Circulation 2003 108: 6-8.
This article has been cited by other articles:
 |
|
 |
|
  S. Sack, P. Kahlert, L. Bilodeau, L. A. Pierard, P. Lancellotti, V. Legrand, J. Bartunek, M. Vanderheyden, R. Hoffmann, P. Schauerte, et al. Percutaneous Transvenous Mitral Annuloplasty: Initial Human Experience With a Novel Coronary Sinus Implant Device Circ Cardiovasc Interv, August 1, 2009; 2(4): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Inan, A. Ucak, A. U. Gullu, and A. T. Yilmaz Iliac Arterial Intussusception From an Aortic Endoclamp Catheter. Ann. Thorac. Surg., July 1, 2009; 88(1): 262 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Bhama, D. Q. Nguyen, S. Scolieri, J. J. Teuteberg, Y. Toyoda, R. L. Kormos, K. R. McCurry, D. McNamara, and C. A. Bermudez Surgical revascularization for cardiac allograft vasculopathy: Is it still an option? J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1488 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Patten Virtual histology intravascular ultrasound assessing the risk of cardiac allograft vasculopathy. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1287 - 1288. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hunt and F. Haddad The Changing Face of Heart Transplantation J. Am. Coll. Cardiol., August 19, 2008; 52(8): 587 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schmauss and M. Weis Cardiac Allograft Vasculopathy: Recent Developments Circulation, April 22, 2008; 117(16): 2131 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 13 - 31. [Abstract] [PDF]
|
|
|
|
 |
|
 P. T. Jindra, Y.-P. Jin, E. Rozengurt, and E. F. Reed HLA Class I Antibody-Mediated Endothelial Cell Proliferation via the mTOR Pathway J. Immunol., February 15, 2008; 180(4): 2357 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]
|
|
|
|
|
|
G. H. Mudge Jr Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"? Circulation, December 4, 2007; 116(23): 2666 - 2668. [Full Text] [PDF]
|
|
|
|
|
|
E. Raichlin, J.-H. Bae, Z. Khalpey, B. S. Edwards, W. K. Kremers, A. L. Clavell, R. J. Rodeheffer, R. P. Frantz, C. Rihal, A. Lerman, et al. Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation Circulation, December 4, 2007; 116(23): 2726 - 2733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt Taking Heart -- Cardiac Transplantation Past, Present, and Future N. Engl. J. Med., July 20, 2006; 355(3): 231 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Isobe, H. Kosuge, and J.-i. Suzuki T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy: Potential Targets for Therapeutic Interventions Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1447 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bakir, F. P. Casselman, F. Wellens, H. Jeanmart, R. De Geest, I. Degrieck, F. Van Praet, Y. Vermeulen, and H. Vanermen Minimally invasive versus standard approach aortic valve replacement: a study in 506 patients. Ann. Thorac. Surg., May 1, 2006; 81(5): 1599 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Hoffman, B. J. Nelson, M. B. Drangstveit, B. M. Flynn, E. A. Watercott, and J. M. Zirbes Caring for Transplant Recipients in a Nontransplant Setting Crit. Care Nurse, April 1, 2006; 26(2): 53 - 73. [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different J. Am. Coll. Cardiol., February 21, 2006; 47(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wessely Interference by interferons: Janus faces in vascular proliferative diseases Cardiovasc Res, June 1, 2005; 66(3): 433 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld, G. G. Miller, S. F. Shakar, R. Zolty, B. D. Lowes, E. E. Wolfel, L. Mestroni, R. L. Page II, and J. Kobashigawa Drug Therapy in the Heart Transplant Recipient: Part II: Immunosuppressive Drugs Circulation, December 21, 2004; 110(25): 3858 - 3865. [Full Text] [PDF]
|
|
|
|
|
|
A. Keogh, M. Richardson, P. Ruygrok, P. Spratt, A. Galbraith, G. O'Driscoll, P. Macdonald, D. Esmore, D. Muller, and S. Faddy Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years: A Randomized Clinical Trial Circulation, October 26, 2004; 110(17): 2694 - 2700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hausleiter, A. Kastrati, J. Mehilli, M. Vogeser, D. Zohlnhofer, H. Schuhlen, C. Goos, J. Pache, F. Dotzer, G. Pogatsa-Murray, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial Circulation, August 17, 2004; 110(7): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Avery Cardiac-Allograft Vasculopathy N. Engl. J. Med., August 28, 2003; 349(9): 829 - 830. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Edelman and H. D. Danenberg Rapamycin for Cardiac Transplant Rejection and Vasculopathy: One Stone, Two Birds? Circulation, July 8, 2003; 108(1): 6 - 8. [Full Text] [PDF]
|
|